거세 저항성 전립선암 치료제 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the castrate resistant prostate cancer therapeutics market size is expected to grow from USD 12.76 billion in 2025 to USD 13.88 billion in 2026 and is forecast to reach USD 21.09 billion by 2031 at 8.74% CAGR over 2026-2031.

This report is Segmented by Treatment Type (Chemotherapy, Hormonal Therapy, Radiation Therapy, and More), Mechanism of Action (AR Signalling Inhibitors, CYP17 Inhibitors, and More), Route of Administration (Oral, Intravenous, Intramuscular/Sub-cutaneous), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Castrate Resistant Prostate Cancer Therapeutics Market Trends and Insights

Growing Aging Male Population & CRPC Prevalence

The demographic tsunami of aging populations represents the most fundamental driver reshaping the CRPC therapeutics landscape. Global prostate cancer incidence is on course to double by 2040, with 10-20% of patients progressing to castrate-resistant disease despite initial hormone control. The aging population's impact extends beyond case volume to treatment complexity, as older patients often present with multiple comorbidities requiring sophisticated therapeutic approaches that balance efficacy with tolerability. Healthcare systems are responding by expanding geriatric oncology capabilities and developing age-appropriate treatment protocols that account for physiological changes in drug metabolism and toxicity profiles.

Wave of Next-Generation AR Inhibitors

Next-generation AR inhibitors have fundamentally altered CRPC treatment paradigms. Darolutamide and apalutamide prolong survival while offering lower seizure risk, leading to accelerated use in both metastatic castration-sensitive and resistant settings. Continuous R&D investment targets AR degraders and dual-pathway inhibitors that further improve clinical durability. The market impact extends beyond efficacy to include improved quality of life metrics, which are increasingly important in regulatory approval decisions and reimbursement negotiations.

High Lifetime Treatment Cost

The substantial financial burden of CRPC treatment creates significant access barriers that limit market expansion, particularly in price-sensitive healthcare systems and emerging markets. Long-term therapy sequences, genomic testing, and adverse-event management push lifetime spend above USD 150,000. Outcome-based contracts and patient-support schemes aim to expand access in price-sensitive regions. The substantial financial burden of CRPC treatment creates significant access barriers that limit market expansion, particularly in price-sensitive healthcare systems and emerging markets.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Survival Data for PARP Inhibitors in HR-Mutated Patients
2. Government-Funded Screening & Awareness Programs
3. Less Than 15% Phase-III Success Rate for Novel Agents

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hormonal therapy contributed 41.22% of CRPC therapeutics market revenue in 2025 due to its entrenched role in androgen suppression. Radiation therapy, buoyed by PSMA-targeted radioligand successes, records the fastest 10.62% CAGR and is expected to capture increasing share of the CRPC therapeutics market size by 2031. Chemotherapy remains a later-line option while immunotherapy and targeted agents broaden treatment diversity.

Clinicians now tailor sequencing around molecular profiling, often introducing radioligand therapy after AR-signaling inhibitor failure. Integration of AI decision tools refines patient selection and aligns therapy with individual disease biology, thereby enhancing response rates and sustaining the CRPC therapeutics market's progression. This technological advancement is particularly important in CRPC management, where treatment resistance mechanisms are complex and require personalized approaches to achieve optimal outcomes.

Complete Report Scope:

• By Treatment Type
  • Chemotherapy
  • Hormonal Therapy
  • Radiation Therapy
  • Other Treatment Types
• By Mechanism of Action
  • AR Signalling Inhibitors
  • CYP17 Inhibitors
  • PSMA-Targeted Therapies
  • DNA-Damage Response Modulators
  • Immune Checkpoint Inhibitors
• By Route of Administration
  • Oral
  • Intravenous
  • Intramuscular/Sub-cutaneous
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.10% of CRPC therapeutics market revenue in 2025, backed by comprehensive insurance coverage, leading research centers, and swift adoption of FDA-approved innovations. Robust clinical-trial density and an established companion diagnostics ecosystem reinforce regional dominance.

Asia-Pacific registers an 10.77% CAGR, the fastest worldwide. China benefits from large patient pools and state-supported oncology infrastructure expansions, while Japan and Australia maintain high baseline adoption of advanced treatments. Growing molecular diagnostic penetration, coupled with national reimbursement adjustments, nudges the CRPC therapeutics market towards higher regional uptake.

Europe remains mature yet opportunity-rich, led by Germany, the United Kingdom, and France. Stringent health-technology assessments enforce real-world evidence requirements, prompting companies to document cost-effectiveness alongside clinical gains. Eastern European health-system upgrades and EU-wide prostate cancer awareness campaigns also contribute to incremental growth.

1. Johnson & Johnson
2. Pfizer Inc / Astellas Pharma
3. Bayer
4. Sanofi
5. AstraZeneca
6. Novartis AG (AAA)
7. Amgen
8. Merck
9. Roche Holding
10. Myovant Sciences
11. Kintor Pharmaceutical
12. Seagen Inc
13. BeiGene
14. Clovis Oncology
15. Nanjing Chia-Tai Tianqing
16. Aragon Pharmaceut. Inc
17. GlaxoSmithKline

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Ageing Male Population & CRPC Prevalence
  • 4.2.2 Wave of Next-Gen Androgen-Receptor (AR) Inhibitors (Darolutamide, Apalutamide)
  • 4.2.3 Favourable Survival Data For PARP-Inhibitors in HR-Mutated Patients
  • 4.2.4 Government-Funded Screening & Awareness Programmes
  • 4.2.5 AI-Enabled Multi-Omics Stratification Driving Responder Identification
  • 4.2.6 Rapid Scale-Up In Lu-177 & Ac-225 Isotope Supply For PSMA-Radioligand Therapy
• 4.3 Market Restraints
  • 4.3.1 High Lifetime Treatment Cost (>$150k/Patient)
  • 4.3.2 <15 % Phase-III Success Rate for Novel Agents
  • 4.3.3 Global Shortfall of Medical-Grade Isotopes for Radiopharmaceuticals
  • 4.3.4 Uneven Reimbursement for Next-Gen Genomic Companion Diagnostics
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Treatment Type
  • 5.1.1 Chemotherapy
  • 5.1.2 Hormonal Therapy
  • 5.1.3 Radiation Therapy
  • 5.1.4 Other Treatment Types
• 5.2 By Mechanism of Action
  • 5.2.1 AR Signalling Inhibitors
  • 5.2.2 CYP17 Inhibitors
  • 5.2.3 PSMA-Targeted Therapies
  • 5.2.4 DNA-Damage Response Modulators
  • 5.2.5 Immune Checkpoint Inhibitors
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
  • 5.3.3 Intramuscular/Sub-cutaneous
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Johnson & Johnson (Janssen)
  • 6.3.2 Pfizer Inc / Astellas Pharma
  • 6.3.3 Bayer AG
  • 6.3.4 Sanofi
  • 6.3.5 AstraZeneca plc
  • 6.3.6 Novartis AG (AAA)
  • 6.3.7 Amgen Inc
  • 6.3.8 Merck & Co.
  • 6.3.9 Roche Holding
  • 6.3.10 Myovant Sciences
  • 6.3.11 Kintor Pharmaceutical
  • 6.3.12 Seagen Inc
  • 6.3.13 BeiGene Ltd
  • 6.3.14 Clovis Oncology
  • 6.3.15 Nanjing Chia-Tai Tianqing
  • 6.3.16 Aragon Pharmaceut. Inc
  • 6.3.17 GlaxoSmithKline plc

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment